The SGLT-2 Inhibitors and their Role in the Treatment of Heart Failure - A Review of Literature
• The purpose of research: Heart failure (HF) is an important global health concern. Despite advancements in treatment, HF remains the leading cause of hospitalization among the elderly. The development of sodium-glucose cotransporter 2 (SGLT2) inhibitors has shown promising cardiovascular and ren...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nicolaus Copernicus University in Toruń
2025-02-01
|
| Series: | Quality in Sport |
| Subjects: | |
| Online Access: | https://apcz.umk.pl/QS/article/view/58178 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1823856453586255872 |
|---|---|
| author | Silvia Ciraolo Agnieszka Kulczycka-Rowicka Joanna Wojda Katarzyna Lesiczka-Fedoryj Anna Walczak Zuzanna Kościuszko Adam Sobiński Matylda Czerwonka Katarzyna Kurza Julianna Podolec |
| author_facet | Silvia Ciraolo Agnieszka Kulczycka-Rowicka Joanna Wojda Katarzyna Lesiczka-Fedoryj Anna Walczak Zuzanna Kościuszko Adam Sobiński Matylda Czerwonka Katarzyna Kurza Julianna Podolec |
| author_sort | Silvia Ciraolo |
| collection | DOAJ |
| description |
• The purpose of research: Heart failure (HF) is an important global health concern. Despite advancements in treatment, HF remains the leading cause of hospitalization among the elderly. The development of sodium-glucose cotransporter 2 (SGLT2) inhibitors has shown promising cardiovascular and renal benefits beyond glucose control. This study aims to explore the potential mechanisms by which SGLT2 inhibitors provide cardiovascular protection, regardless of type 2 diabetes mellitus (T2DM).
• Research materials and methods: A comprehensive literature review was conducted, analyzing clinical trials, guideline documents, and mechanistic studies on SGLT2 inhibitors. Definitions and classifications of HF, risk factors, and cardiovascular effects of SGLT2 inhibitors were reviewed. Key studies such as EMPA-REG OUTCOME, DAPA-HF, and others were analyzed to identify mechanisms contributing to cardiovascular protection.
• Results: SGLT2 inhibitors provide cardiovascular benefits in HF patients, regardless of T2DM status. Key mechanisms include natriuresis, improved cardiac metabolism, reduced inflammation, prevention of cardiac remodeling, sympathetic inhibition, enhanced vascular health, and better kidney function.
• Conclusions: The benefits of SGLT2 inhibitors extend beyond glucose control. They provide various effects, including improved hemodynamics, reduced inflammation, and enhanced cardiac energy metabolism. While several mechanisms have been proposed, further research is necessary to rule which are most critical. The benefits observed with SGLT2 inhibitors stress their potential as a cornerstone in HF management, regardless of a patient’s diabetes status.
|
| format | Article |
| id | doaj-art-c3424aca6b0a4be7b3566e68ca9991a0 |
| institution | Kabale University |
| issn | 2450-3118 |
| language | English |
| publishDate | 2025-02-01 |
| publisher | Nicolaus Copernicus University in Toruń |
| record_format | Article |
| series | Quality in Sport |
| spelling | doaj-art-c3424aca6b0a4be7b3566e68ca9991a02025-02-12T08:26:13ZengNicolaus Copernicus University in ToruńQuality in Sport2450-31182025-02-013810.12775/QS.2025.38.58178The SGLT-2 Inhibitors and their Role in the Treatment of Heart Failure - A Review of LiteratureSilvia Ciraolo0https://orcid.org/0009-0005-7010-5195Agnieszka Kulczycka-Rowicka1https://orcid.org/0009-0009-8917-4042Joanna Wojda2https://orcid.org/0009-0006-2662-8893Katarzyna Lesiczka-Fedoryj3https://orcid.org/0009-0004-4213-3028Anna Walczak4https://orcid.org/0009-0004-4554-9598Zuzanna Kościuszko5https://orcid.org/0009-0008-1490-8569Adam Sobiński6https://orcid.org/0009-0003-3063-5621Matylda Czerwonka7https://orcid.org/0009-0000-9738-9646Katarzyna Kurza8https://orcid.org/0009-0009-0075-2257Julianna Podolec9https://orcid.org/0009-0000-6980-7046University Clinical Hospital in Bialystok: Bialystok, PL Maria Skłodowska- Curie 24A, 15-276 BialystokŚniadeckiego Voivodeship Hospital in Bialystok: BiałystokUniversity Clinical Hospital in Bialystok: Białystok, PL Maria Skłodowska- Curie 24A, 15-276 BialystokHospital in Puszczykowo: Puszczykowo, PLŚniadeckiego Voivodeship Hospital in Bialystok: Białystok, PLFlorian Ceynowy Specialist Hospital in Wejherowo: Wejherowo, PLMEDAR Private Healthcare Facility in LeczycaŚniadeckiego Voivodeship Hospital in BiałystokIndependent Public Health Care Facility in MysleniceUniversity Clinical Hospital in Bialystok • The purpose of research: Heart failure (HF) is an important global health concern. Despite advancements in treatment, HF remains the leading cause of hospitalization among the elderly. The development of sodium-glucose cotransporter 2 (SGLT2) inhibitors has shown promising cardiovascular and renal benefits beyond glucose control. This study aims to explore the potential mechanisms by which SGLT2 inhibitors provide cardiovascular protection, regardless of type 2 diabetes mellitus (T2DM). • Research materials and methods: A comprehensive literature review was conducted, analyzing clinical trials, guideline documents, and mechanistic studies on SGLT2 inhibitors. Definitions and classifications of HF, risk factors, and cardiovascular effects of SGLT2 inhibitors were reviewed. Key studies such as EMPA-REG OUTCOME, DAPA-HF, and others were analyzed to identify mechanisms contributing to cardiovascular protection. • Results: SGLT2 inhibitors provide cardiovascular benefits in HF patients, regardless of T2DM status. Key mechanisms include natriuresis, improved cardiac metabolism, reduced inflammation, prevention of cardiac remodeling, sympathetic inhibition, enhanced vascular health, and better kidney function. • Conclusions: The benefits of SGLT2 inhibitors extend beyond glucose control. They provide various effects, including improved hemodynamics, reduced inflammation, and enhanced cardiac energy metabolism. While several mechanisms have been proposed, further research is necessary to rule which are most critical. The benefits observed with SGLT2 inhibitors stress their potential as a cornerstone in HF management, regardless of a patient’s diabetes status. https://apcz.umk.pl/QS/article/view/58178SGLT2 inhibitorsHeart failurebenefitscardiovascular effects |
| spellingShingle | Silvia Ciraolo Agnieszka Kulczycka-Rowicka Joanna Wojda Katarzyna Lesiczka-Fedoryj Anna Walczak Zuzanna Kościuszko Adam Sobiński Matylda Czerwonka Katarzyna Kurza Julianna Podolec The SGLT-2 Inhibitors and their Role in the Treatment of Heart Failure - A Review of Literature Quality in Sport SGLT2 inhibitors Heart failure benefits cardiovascular effects |
| title | The SGLT-2 Inhibitors and their Role in the Treatment of Heart Failure - A Review of Literature |
| title_full | The SGLT-2 Inhibitors and their Role in the Treatment of Heart Failure - A Review of Literature |
| title_fullStr | The SGLT-2 Inhibitors and their Role in the Treatment of Heart Failure - A Review of Literature |
| title_full_unstemmed | The SGLT-2 Inhibitors and their Role in the Treatment of Heart Failure - A Review of Literature |
| title_short | The SGLT-2 Inhibitors and their Role in the Treatment of Heart Failure - A Review of Literature |
| title_sort | sglt 2 inhibitors and their role in the treatment of heart failure a review of literature |
| topic | SGLT2 inhibitors Heart failure benefits cardiovascular effects |
| url | https://apcz.umk.pl/QS/article/view/58178 |
| work_keys_str_mv | AT silviaciraolo thesglt2inhibitorsandtheirroleinthetreatmentofheartfailureareviewofliterature AT agnieszkakulczyckarowicka thesglt2inhibitorsandtheirroleinthetreatmentofheartfailureareviewofliterature AT joannawojda thesglt2inhibitorsandtheirroleinthetreatmentofheartfailureareviewofliterature AT katarzynalesiczkafedoryj thesglt2inhibitorsandtheirroleinthetreatmentofheartfailureareviewofliterature AT annawalczak thesglt2inhibitorsandtheirroleinthetreatmentofheartfailureareviewofliterature AT zuzannakosciuszko thesglt2inhibitorsandtheirroleinthetreatmentofheartfailureareviewofliterature AT adamsobinski thesglt2inhibitorsandtheirroleinthetreatmentofheartfailureareviewofliterature AT matyldaczerwonka thesglt2inhibitorsandtheirroleinthetreatmentofheartfailureareviewofliterature AT katarzynakurza thesglt2inhibitorsandtheirroleinthetreatmentofheartfailureareviewofliterature AT juliannapodolec thesglt2inhibitorsandtheirroleinthetreatmentofheartfailureareviewofliterature AT silviaciraolo sglt2inhibitorsandtheirroleinthetreatmentofheartfailureareviewofliterature AT agnieszkakulczyckarowicka sglt2inhibitorsandtheirroleinthetreatmentofheartfailureareviewofliterature AT joannawojda sglt2inhibitorsandtheirroleinthetreatmentofheartfailureareviewofliterature AT katarzynalesiczkafedoryj sglt2inhibitorsandtheirroleinthetreatmentofheartfailureareviewofliterature AT annawalczak sglt2inhibitorsandtheirroleinthetreatmentofheartfailureareviewofliterature AT zuzannakosciuszko sglt2inhibitorsandtheirroleinthetreatmentofheartfailureareviewofliterature AT adamsobinski sglt2inhibitorsandtheirroleinthetreatmentofheartfailureareviewofliterature AT matyldaczerwonka sglt2inhibitorsandtheirroleinthetreatmentofheartfailureareviewofliterature AT katarzynakurza sglt2inhibitorsandtheirroleinthetreatmentofheartfailureareviewofliterature AT juliannapodolec sglt2inhibitorsandtheirroleinthetreatmentofheartfailureareviewofliterature |